- Home
- AEE vs UTHR Comparison
AEE vs UTHR Comparison
Compare AEE & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEE
- UTHR
- Stock Information
- Founded
- AEE 1901
- UTHR 1996
- Country
- AEE United States
- UTHR United States
- Employees
- AEE N/A
- UTHR N/A
- Industry
- AEE Power Generation
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- AEE Utilities
- UTHR Health Care
- Exchange
- AEE Nasdaq
- UTHR Nasdaq
- Market Cap
- AEE 25.7B
- UTHR 14.4B
- IPO Year
- AEE N/A
- UTHR 1999
- Fundamental
- Price
- AEE $96.36
- UTHR $289.53
- Analyst Decision
- AEE Buy
- UTHR Buy
- Analyst Count
- AEE 11
- UTHR 13
- Target Price
- AEE $101.27
- UTHR $386.15
- AVG Volume (30 Days)
- AEE 1.8M
- UTHR 719.7K
- Earning Date
- AEE 07-31-2025
- UTHR 07-30-2025
- Dividend Yield
- AEE 2.95%
- UTHR N/A
- EPS Growth
- AEE 3.54
- UTHR 18.86
- EPS
- AEE 4.51
- UTHR 25.10
- Revenue
- AEE $7,596,000,000.00
- UTHR $2,994,100,000.00
- Revenue This Year
- AEE $12.63
- UTHR $14.30
- Revenue Next Year
- AEE $5.26
- UTHR $6.32
- P/E Ratio
- AEE $21.37
- UTHR $11.55
- Revenue Growth
- AEE 9.04
- UTHR 19.84
- 52 Week Low
- AEE $70.15
- UTHR $266.98
- 52 Week High
- AEE $104.10
- UTHR $417.82
- Technical
- Relative Strength Index (RSI)
- AEE 49.98
- UTHR 44.13
- Support Level
- AEE $95.02
- UTHR $282.42
- Resistance Level
- AEE $96.13
- UTHR $290.00
- Average True Range (ATR)
- AEE 1.22
- UTHR 7.70
- MACD
- AEE 0.13
- UTHR -0.43
- Stochastic Oscillator
- AEE 63.36
- UTHR 74.44
About AEE Ameren Corporation
Ameren owns rate-regulated generation, transmission, and distribution networks that deliver electricity and natural gas in Missouri and Illinois. It serves 2.5 million electricity customers and approximately 1 million natural gas customers.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.